VICTORIS
Budget Express 2026

co-presented by

  • LIC
  • JIO BlackRock

ASSOCIATE SPONSORS

  • Sunteck
  • SBI
  • Emirates
  • Dezerv
Get App Open
In App
News on WhatsApp
News on WhatsApp
Open App
VICTORIS
Budget Express 2026

co-presented by

  • LIC
  • JIO BlackRock

ASSOCIATE SPONSORS

  • Sunteck
  • SBI
  • Emirates
  • Dezerv

Piramal Phytocare Ltd.

BSE: 532979 | NSE: PIRPHYTO | Series: NA | ISIN: INE122J01015 | SECTOR: Biotechnology & Medical Research

BSE Live

Dec 10, 16:00
22.55 0.00 (0.00%)
Volume
No Data Available
0
  • Prev. Close

    22.55

  • Open Price

    22.40

  • Bid Price (Qty.)

    22.50 (25)

  • Offer Price (Qty.)

    24.50 (100)

Piramal Phytocare is not traded on BSE in the last 30 days

NSE Live

Dec 10, 15:31
22.70 0.00 (0.00%)
Volume
No Data Available
0
  • Prev. Close

    22.70

  • Open Price

    22.05

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Piramal Phytocare is not traded on NSE in the last 30 days
Company History - Piramal Phytocare
Piramal Life Sciences Limited, is an independent research driven drug
 Company that was recently demerged from Piramal Healthcare Limited
 (Formerly know as Nicholas Piramal India Limited). PLSL was formerly
 the NCE R&D division of NPIL. PLSL has state-of-the-art R&D
 laboratories built over 200,000 square-feet of space in Mumbai, India
 and over 300 scientists engaged in drug discovery and development. 
 PLSL is focused on four therapeutic areas.  Cancer, Diabetes,
 Inflammation and Infectious Diseases. The Company has a pipeline of
 fourteen compounds, including four in clinical trials. PLSL's lead
 chemical compound, a Cdk-4 inhibitor, has completed two phase 1
 studies and is being tested in another Phase I/II trials for Multiple
 Myeloma. PLSL has drug discovery and developments agreements with Eli
 Lilly & Company and Merck & Company, two of the leading
 pharmaceuticals companies in the world.
 PLSL is expected to be listed on the National Stock Exchange and the
 Bombay Stock Exchange by June 2008. 
 
 2008
 
 -Piramal Life Sciences gets its shares listed in the Stock Exchange.
 
 -Piramal receives approval for clinical trial of two drugs
 
 -Piramal Life Sciences Limited has received regulatory approval for
 the initiation of a Phase I study of a new cancer compound,
 P-1446A-05, in Canada
 
 2009
 
 -Piramal Life Sciences initiates Phase II trials of P276 for Mantle
 Cell Lymphoma
 
 -Piramal Life Sciences receives DCGI Approval to conduct two Phase
 I/II Combination studies of it's cancer molecule P276 for pancreatic,
 and head and neck cancer. 
 
 2010
 
 -Piramal Life Sciences changes its Share Transfer Agent from M/s.
 Freedom Registry Ltd. to M/s. Link Intime India Pvt. Ltd.
 
 -Piramal Life Sciences initiates Phase II Trials for P1736-05 for
 Type II Diabetes in India and Europe
 
 2012
 
 -Mr. Ankit Sheth has been appointed as Company Secretary of the
 Company.
 
 
 2013
 
 -The company name has been changed from Piramal Life Sciences Limited
 to Piramal Phytocare Limited .
 -The trading symbol of the Company be changed from PIRLIFE to
 PIRPHYTO.
 
Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347